Completed

The Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Platelet Lysate

Biological
Who is being recruted

From 21 to 78 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Phase 1 & 2
Interventional
Study Start: February 2017
See protocol details

Summary

Principal SponsorHanan Jafar
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: February 16, 2017

Actual date on which the first participant was enrolled.

Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be taken in multiple doses.

Official TitleThe Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects
NCT02979912
Principal SponsorHanan Jafar
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

10 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.



Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 21 to 78 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Criteria

4 inclusion criteria required to participate
Cognitive ability to understand and sign the consent form.

Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic eye-drops).

Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy, corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal lesions due to a foreign body.

Good compliance with the study regimen and availability for the duration of the entire study period.

2 exclusion criteria prevent from participating
Corneal ulcers which developed tissue scars.

Pregnant or lactating women.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Group I

Experimental
Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Cell Therapy Center

Amman, JordanOpen Cell Therapy Center in Google Maps
CompletedOne Study Center